MRKR

Marker Therapeutics Inc

MRKR, USA

Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Its multi tumor associated antigen-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens. The company also develops MT-401-OTS for the treatment of acute myeloid leukemia AND myelodysplastic syndromes; and MT-601 to treat lymphoma and pancreatic cancer. Marker Therapeutics, Inc. is headquartered in Houston, Texas.

https://markertherapeutics.com

Stock Price

$ 0.00

0% increase compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
MRKR
stock
MRKR

Top Growth Drivers Behind Sri Krishna Constructions India Limited Stocks Recent Surge - Stock Price Divergence & Low Risk Wealth Building earlytimes.in

Read more →
MRKR
stock
MRKR

FY2025 Earnings Forecast for MRKR Issued By HC Wainwright Defense World

Read more →

Showing 2 of 10

Analyst Ratings & Sentiment

(Last Updated 2025-09-30)

Rating:

STRONG BUY

Target Price:

$6

Analyst Picks

Strong Buy

2

Buy

0

Hold

0

Sell

0

Strong Sell

0

Sentiment:

Bullish

Finn Analysis

(Last Updated 2025-09-30)

Health Score

Price to Book Ratio (P/B)

-

Very Low

1.34

Low ≤ 1

High ≥ 3

Return on Equity (ROE)

-

Very Low

-10.87 %

Low ≤ 5%

High ≥ 25%

Return on Assets (ROA)

-

Very Low

-9.20 %

Low ≤ 2%

High ≥ 10%

Free Cash Flow - Revenue % (FCF)

-

Very Low

-221.90 %

Low ≤ 5%

High ≥ 15%

Debt to Equity

-

Very High

0.18

Low ≥ 1

High ≤ 0.3

Investors

* Institutions hold a combined 29.54% of the total shares of Marker Therapeutics Inc

1.

NEA Management Company, LLC

(12.5643%)

since

2025/06/30

2.

Blue Owl Capital Holdings LP

(4.2836%)

since

2025/06/30

3.

Aisling Capital Management LP

(2.5147%)

since

2025/06/30

4.

Vanguard Group Inc

(2.128%)

since

2025/06/30

5.

Alyeska Investment Group, L.P.

(1.6464%)

since

2025/06/30

6.

Vanguard Total Stock Mkt Idx Inv

(1.4045%)

since

2025/07/31

7.

Geode Capital Management, LLC

(0.7402%)

since

2025/06/30

8.

Vanguard Institutional Extnd Mkt Idx Tr

(0.6822%)

since

2025/07/31

9.

LPL Financial Corp

(0.57%)

since

2025/06/30

10.

Renaissance Technologies Corp

(0.5367%)

since

2025/06/30

11.

Fidelity Extended Market Index

(0.3664%)

since

2025/07/31

12.

Vifag 2002 SICAV

(0.2319%)

since

2025/07/31

13.

Invst LLC

(0.1808%)

since

2025/03/31

14.

Jane Street Group LLC

(0.1685%)

since

2025/06/30

15.

State Street Corp

(0.1619%)

since

2025/06/30

16.

Advisor Group Holdings, Inc.

(0.1513%)

since

2025/06/30

17.

Creative Planning Inc

(0.1338%)

since

2025/06/30

18.

Dimensional Fund Advisors, Inc.

(0.1229%)

since

2025/06/30

19.

Matrix Asset Advisors Inc

(0.1159%)

since

2025/06/30

20.

Fidelity Series Total Market Index

(0.1073%)

since

2025/07/31

21.

Fidelity Total Market Index

(0.099%)

since

2025/07/31

22.

Spartan Extended Market Index Pool F

(0.0967%)

since

2025/07/31

23.

Susquehanna International Group, LLP

(0.0961%)

since

2025/06/30

24.

Northern Trust Corp

(0.0839%)

since

2025/06/30

25.

NT Ext Equity Mkt Idx Fd - NL

(0.0448%)

since

2025/06/30

26.

Fidelity Nasdaq Composite Index

(0.0407%)

since

2025/07/31

27.

NT Ext Equity Mkt Idx Fd - L

(0.0367%)

since

2025/06/30

28.

Northern Trust Extended Eq Market Idx

(0.0367%)

since

2025/06/30

29.

Spartan Total Market Index Pool G

(0.0353%)

since

2025/07/31

30.

NT Ext Equity Mkt Idx Fd - DC - NL - T2

(0.0348%)

since

2025/06/30

31.

Tower Research Capital LLC

(0.0261%)

since

2025/06/30

32.

Vanguard U.S. Eq Idx £ Acc

(0.0194%)

since

2025/07/31

33.

State St US Extended Mkt Indx NL Cl C

(0.0157%)

since

2025/08/31

34.

SBI Securities Co Ltd

(0.0132%)

since

2025/06/30

35.

UBS Group AG

(0.0124%)

since

2025/06/30

36.

NT Ext Eq Mkt Indx Fd DC Lending Tier 5

(0.0104%)

since

2025/06/30

37.

NT Ext Eq Mkt Indx Fd DC Lend T3

(0.0087%)

since

2024/12/31

38.

BNYM Mellon SL Market Completion UC1

(0.0087%)

since

2025/06/30

39.

SSgA U.S. Total Market Index Strategy

(0.0066%)

since

2025/03/31

40.

Northern Trust Wilshire 5000

(0.0024%)

since

2025/06/30

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

—

EPS Estimate

—

Latest Release

Date

2025-09-30

EPS Actual

-0.12

EPS Estimate

-0.21

EPS Difference

0.09

Surprise Percent

42.8571%

Investing Fit Scorecard

(Last Updated 2025-09-30)

Deep Value
Potential Value Candidate(6)
Defensive
Highly Defensive(7)
Dividend
Weak Dividend Profile(1.5)
Economic Moat
Some Competitive Advantage(5.3)
GARP
Fair GARP(4.5)
Growth
Weak Growth Prospect(3)
Momentum
Moderate Momentum(4)
Net Net
Possible Net-Net(6)
Quality
Low Quality Business(3)
Value
Undervalued(6.5)

Income Statement

(Last Updated 2025-09-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-09-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2025-09-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.